Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Candel Therapeutics Inc
(NQ:
CADL
)
10.15
+0.83 (+8.90%)
Streaming Delayed Price
Updated: 1:47 PM EDT, May 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Candel Therapeutics Inc
< Previous
1
2
Next >
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
April 25, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
April 11, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
April 09, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Unusually High Volume Points to Upside in These Stocks
April 05, 2024
Unusually high volume is often a signal of higher price to come; this is a look at three stocks with recent volume spikes and a reason for the price to advance.
Via
MarketBeat
Topics
ETFs
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
April 04, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
March 28, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
March 28, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
March 06, 2024
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END
Via
FinancialNewsMedia
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
March 05, 2024
From
Candel Therapeutics
Via
GlobeNewswire
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
February 13, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
February 05, 2024
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
December 12, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
November 28, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
November 09, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
November 04, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
November 03, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
October 18, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
September 27, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
September 26, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
August 10, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
June 13, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
June 08, 2023
Nicoletta Loggia, PhD, RPh, biopharma executive with more than two decades of technical expertise in the biopharmaceutical industry
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
June 05, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
May 19, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 11, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
May 02, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
April 17, 2023
Fast track designation has the potential to facilitate the development and expedite the U.S. FDA review of CAN-2409 plus valacyclovir and anti-PD1 antibodies in patients with stage III/IV non-small...
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
March 30, 2023
From
Candel Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.